<DOC>
	<DOC>NCT01758887</DOC>
	<brief_summary>- Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? - What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis? - What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?</brief_summary>
	<brief_title>Antipsychotic Discontinuation in High-risk Subjects</brief_title>
	<detailed_description>After the antipsychotic medication discontinuation, we are going to assess the changes of the biological markers</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosed as a clinical High Risk Treated with antipsychotic drugs PSP15 (from SIPS criteria) &lt;3 (severity index)for more than 6 months Had not experienced a symptomatic relapse in the 6 months Significant abnormality in laboratory tests History of head trauma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>